These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27852211)

  • 41. March of the synthesis machines.
    Sanderson K
    Nat Rev Drug Discov; 2015 May; 14(5):299-300. PubMed ID: 25924572
    [No Abstract]   [Full Text] [Related]  

  • 42. Forewords BMC.
    Gallou F
    Bioorg Med Chem; 2018 Aug; 26(14):4329. PubMed ID: 29983282
    [No Abstract]   [Full Text] [Related]  

  • 43. Detour matrix-based adjacent path eccentric distance sum indices for QSAR/QSPR. Part I: development and evaluation.
    Singh M; Bharatam PV; Madan AK
    Int J Comput Biol Drug Des; 2014; 7(4):295-318. PubMed ID: 25539844
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemical stability of nucleic acid-derived drugs.
    Pogocki D; Schöneich C
    J Pharm Sci; 2000 Apr; 89(4):443-56. PubMed ID: 10737906
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantitative structure-toxicity relationships by accelerated cytotoxicity mechanism screening.
    Siraki AG; Chevaldina T; Moridani MY; O'Brien PJ
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):118-25. PubMed ID: 14982155
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-throughput and parallel screening methods in asymmetric hydrogenation.
    Jäkel C; Paciello R
    Chem Rev; 2006 Jul; 106(7):2912-42. PubMed ID: 16836304
    [No Abstract]   [Full Text] [Related]  

  • 47. Combinatorial chemistry hits the drug market.
    Service RF
    Science; 1996 May; 272(5266):1266-8. PubMed ID: 8650537
    [No Abstract]   [Full Text] [Related]  

  • 48. Combinatorial organic synthesis and the lead discovery process.
    Villalgordo JM
    Methods Find Exp Clin Pharmacol; 1997; 19 Suppl A():37-41. PubMed ID: 9403855
    [No Abstract]   [Full Text] [Related]  

  • 49. [Chemoinformatics and virtual screening of molecules for therapeutic use].
    Vayer P; Arrault A; Lesur B; Bertrand M; Walther B
    Med Sci (Paris); 2009 Oct; 25(10):871-7. PubMed ID: 19849994
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and validation of AMANDA, a new algorithm for selecting highly relevant regions in Molecular Interaction Fields.
    Durán A; Martínez GC; Pastor M
    J Chem Inf Model; 2008 Sep; 48(9):1813-23. PubMed ID: 18693718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chirality and its importance in drug development.
    Campbell DB; Wilson K
    Biochem Soc Trans; 1991 Apr; 19(2):472-5. PubMed ID: 1889635
    [No Abstract]   [Full Text] [Related]  

  • 52. [Computer-designed site-specific drugs--myth or reality?].
    Taskinen J
    Duodecim; 1995; 111(8):799-806. PubMed ID: 8681840
    [No Abstract]   [Full Text] [Related]  

  • 53. Ligand efficiency indices as guideposts for drug discovery.
    Abad-Zapatero C; Metz JT
    Drug Discov Today; 2005 Apr; 10(7):464-9. PubMed ID: 15809192
    [No Abstract]   [Full Text] [Related]  

  • 54. Process chemistry: The science, business, logic, and logistics.
    Zhang TY
    Chem Rev; 2006 Jul; 106(7):2583-95. PubMed ID: 16836293
    [No Abstract]   [Full Text] [Related]  

  • 55. Molecular modelling.
    Barril X; Soliva R
    Mol Biosyst; 2006 Dec; 2(12):660-81. PubMed ID: 17216047
    [No Abstract]   [Full Text] [Related]  

  • 56. Analysis of the reactions used for the preparation of drug candidate molecules.
    Carey JS; Laffan D; Thomson C; Williams MT
    Org Biomol Chem; 2006 Jun; 4(12):2337-47. PubMed ID: 16763676
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Computational prediction of drug solubility in water-based systems: Qualitative and quantitative approaches used in the current drug discovery and development setting.
    Bergström CAS; Larsson P
    Int J Pharm; 2018 Apr; 540(1-2):185-193. PubMed ID: 29421301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A priori performance predictions in the pharmaceutical sciences.
    Hancock BC; Morris KR; Wildfong PL
    Int J Pharm; 2011 Oct; 418(2):149-50. PubMed ID: 21726614
    [No Abstract]   [Full Text] [Related]  

  • 59. Race for molecular summits.
    Service RF
    Science; 1999 Jul; 285(5425):184-5, 187. PubMed ID: 10428711
    [No Abstract]   [Full Text] [Related]  

  • 60. De novo drug design.
    Hartenfeller M; Schneider G
    Methods Mol Biol; 2011; 672():299-323. PubMed ID: 20838974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.